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Morbidity and Mortality Weekly Report

Advisory Committee on Immunization Practices Recommended
Immunization Schedule for Children and Adolescents
Aged 18 Years or Younger — United States, 2019
Candice L. Robinson, MD1; Henry Bernstein, MD2; José R. Romero, MD3,4; Peter Szilagyi, MD5

At its October 2018 meeting, the Advisory Committee on
Immunization Practices (ACIP)* voted to recommend approval
of the Recommended Immunization Schedule for Children
and Adolescents Aged 18 Years or Younger, United States,
2019. The 2019 child and adolescent immunization schedule
summarizes ACIP recommendations, including several changes
from the 2018 immunization schedule,† on the cover page,
three tables, and notes found on the CDC immunization
schedule website (https://www.cdc.gov/vaccines/schedules/
index.html). This immunization schedule is recommended
by ACIP and approved by the CDC Director, the American
Academy of Pediatrics, the American Academy of Family
Physicians, and the American College of Obstetricians and
Gynecologists. Health care providers are advised to use the
tables and the notes together.
ACIP’s recommendations on use of each vaccine are developed after in-depth reviews of vaccine-related data, including
disease epidemiology and burden, vaccine efficacy and effectiveness, vaccine safety, quality of evidence, feasibility of program implementation, and economic analyses of immunization
policy (1). The child and adolescent immunization schedule
is published annually to consolidate and summarize updates
to ACIP recommendations on vaccination of children and
adolescents and to assist health care providers in implementing
current ACIP recommendations. The use of trade names of
vaccines in this report and in the child and adolescent immunization schedule is for identification purposes only and does
not imply endorsement by ACIP or CDC.
For further guidance on the use of each vaccine, including
contraindications and precautions, health care providers are
referred to the respective ACIP vaccine recommendations
* Recommendations for routine use of vaccines in children and adolescents are
developed by ACIP, a federal advisory committee chartered to provide expert
external advice and guidance to the CDC Director on use of vaccines and related
agents for the control of vaccine-preventable diseases in the civilian population
of the United States. Recommendations for routine use of vaccines in children
and adolescents are harmonized to the greatest extent possible with
recommendations made by the American Academy of Pediatrics, the American
Academy of Family Physicians, and the American College of Obstetricians and
Gynecologists. ACIP recommendations approved by the CDC Director become
agency guidelines on the date published in the Morbidity and Mortality Weekly
Report. Additional information about ACIP is available at https://www.cdc.gov/
vaccines/acip.
† Past immunization schedules are available at https://www.cdc.gov/vaccines/
schedules/past.html.
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at https://www.cdc.gov/vaccines/hcp/acip-recs/index.html.
Changes in recommended use of vaccines can occur between
annual updates to the child and adolescent immunization
schedule. These changes, if made, are available at https://www.
cdc.gov/vaccines/acip/recommendations.html).§ Printable versions of the 2019 child and adolescent immunization schedule
and ordering instructions are available on the immunization
schedule website.

Vaccine Changes in the 2019 Immunization
Schedule for Children and Adolescents
Vaccine changes in the 2019 immunization schedule for
children and adolescents aged ≤18 years include new or revised
ACIP recommendations for hepatitis A vaccine (HepA) (2),
hepatitis B vaccine (Hep B) (3), influenza vaccine (4), and tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis
vaccine (Tdap) (5), as well as clarification of the recommendations for inactivated poliovirus vaccines (IPV).

Changes Affecting Multiple Portions of the
Schedule
The overall appearance of the 2019 child and adolescent
schedule has been updated because of recommendations resulting from a recent evaluation of the child and adolescent immunization schedule. An internet survey of 249 pediatricians
and family medicine physicians was conducted to assess their
familiarity with the schedule, the environment in which the
schedule is used, the frequency and circumstances of use, and
their impressions and preferences on redesigned drafts of the
child and adolescent immunization schedule. These changes
have been applied to all portions of the immunization schedule, including the cover page, routine immunization schedule
§ CDC

encourages organizations to use syndication as a more reliable method
for displaying the most current and accurate immunization schedules on an
organization’s website rather than copying these schedules to their websites.
Use of content syndication requires a one-time step that ensures an organization’s
website displays current schedules as soon as they are published or revised;
instructions for the syndication code are available on CDC’s website (https://
www.cdc.gov/vaccines/schedules/syndicate.html). CDC also offers technical
assistance for implementing this form of content syndication (e-mail request
to ncirdwebteam@cdc.gov). Changes in ACIP recommendations in the child
and adolescent immunization schedule before the next scheduled annual update,
if any, are available at https://www.cdc.gov/vaccines/schedules/hcp/childadolescent.html.
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(Table 1), catch-up schedule (Table 2), medical indications for
each vaccine (Table 3), and notes with details for each vaccine.
Cover Page. Changes to the cover page are as follows:
• Guidance on how to use the schedule was added to the
top of the document.
• Live attenuated influenza vaccine (LAIV) was added to
the vaccine table.
• A Helpful Information section, which includes links to the
ACIP recommendations, the General Best Practice Guidelines
for Immunization, and the Manual for the Surveillance of
Vaccine-Preventable Diseases, has been added.
Table 1. Changes to Table 1 (previously known as Figure 1)
are as follows:
• A separate row has been added for LAIV.
• A purple bar has been added to the Hepatitis A (HepA)
row at age 6–11 months to represent use in infant travelers.
• Within the Tetanus, diphtheria, & acellular pertussis
(Tdap: ≥7 yrs) row, the bar for persons aged 13–18 years
has been split into a half green and half purple bar to
represent catch-up vaccination and use in pregnant
adolescents, respectively.
Table 2. Changes to Table 2 (previously known as Figure 2)
are as follows:
• Minor changes to the order in which guidance is presented
in the Haemophilius influenzae type b and Pneumococcal
conjugate rows were made. The criteria under which no
further doses are needed are now presented first, followed
by recommendation for those for whom additional doses
are indicated.
Table 3. Changes to Table 3 (previously known as Figure 3)
are as follows:
• A new pink color has been added to the legend, which
represents “Delay vaccination until after pregnancy if
vaccine indicated.” This color is used in the pregnancy
column for human papillomavirus vaccine.
• The Contraindicated and Precaution for vaccination boxes
in the legend have been defined with narrative text.
• A row for LAIV has been added.
• The Pregnancy cell in the meningococcal B vaccine row has
been changed to the orange Precaution for vaccination color.
Notes. The notes (previously known as footnotes) are
presented in alphabetical order rather than linked by numerical superscripts as in previous years. Edits have been made
throughout the Notes section to harmonize language between
the child and adolescent schedule and the adult immunization
schedule, where possible. In addition, the following content
changes were made:

• The HepA note was revised to include information
regarding the use of combined HepA-HepB vaccine in
persons aged ≥18 years. A section for international travel
has been added with recommendations for vaccination of
travelers aged 6–11 months and unvaccinated travelers
aged ≥12 months. Homelessness also has been added as
an indication for HepA vaccination.
• The HepB note was revised to include information regarding
the use of CpG-adjuvanted HepB vaccine and combination
HepA-HepB vaccine in persons aged ≥18 years.
• Within the IPV note, a bullet has been added regarding
the use of combination vaccines that contain IPV.
• The Influenza vaccines note has been updated to indicate
that LAIV can be used during the 2018–19 influenza
season. A Special Situations section has been added with
information regarding vaccination of persons with a
history of egg allergy and circumstances under which LAIV
use is not recommended.
• During mumps and meningococcal disease outbreaks, the
Additional Information section at the beginning of the
notes directs providers to their state or local health
department for information regarding vaccination during
an outbreak. Therefore, language regarding the use of
measles, mumps, and rubella (MMR) vaccine in the setting
of a mumps outbreak or the use of meningococcal (groups
A, C, W-135, and Y) conjugate (MenACWY) and
meningococcal group B (MenB) vaccines in the setting of
meningococcal disease outbreaks has been removed from
the MMR and meningococcal vaccine notes.
• The Tdap note has been updated to indicate that those
persons who received a dose of Tdap or diphtheria and
tetanus toxoids and acellular pertussis vaccine (DTaP) at
age 7–10 years inadvertently or as part of the catch-up
series should still receive the routine dose of Tdap at age
11–12 years. A link to information regarding use of Tdap/
tetanus and diphtheria toxoids (Td) for wound prophylaxis
also has been added.
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